Citation Impact
Citing Papers
LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus–negative Head and Neck Squamous Cell Carcinoma
2019
Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
2019
Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X L
2019
The Outgrowth of Micrometastases Is Enabled by the Formation of Filopodium-like Protrusions
2012
Neutrophils Suppress Intraluminal NK Cell–Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells
2016
Integrin β 1 -focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs
2009
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
The isoquinoline PRL-295 increases the thermostability of Keap1 and disrupts its interaction with Nrf2
2021
Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness
2016
Degradation of proteins by PROTACs and other strategies
2019
Advances in targeted degradation of endogenous proteins
2019
The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers
2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
2016
Hallmarks of Cancer: The Next Generation
2011 Standout
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
2021
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
2020
Inhibitors of the p53/hdm2 protein–protein interaction—path to the clinic
2013
Cellular interactions in metastasis
1990
Recent Researches in Triazole Compounds as Medicinal Drugs
2012
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
The Cellular Basis of Tumor Progression
1997
Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
2017
Multifunctional Lipid/Quantum Dot Hybrid Nanocontainers for Controlled Targeting of Live Cells
2006 StandoutNobel
Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents
2013
The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells
2014
The PROTACtable genome
2021
Cancer to bone: a fatal attraction
2011 Standout
Exploring Targeted Degradation Strategy for Oncogenic KRASG12C
2019
The cancer glycocalyx mechanically primes integrin-mediated growth and survival
2014 StandoutNatureNobel
Targeting IAP proteins for therapeutic intervention in cancer
2012
Drugging the p53 pathway: understanding the route to clinical efficacy
2014
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
2020
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
2020
Peptide therapeutics: Targeting the undruggable space
2015
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
2017
Recent advances in organocatalytic methods for the synthesis of disubstituted 2- and 3-indolinones
2012 Standout
Dissemination and growth of cancer cells in metastatic sites
2002 Standout
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
2010
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
NF-κB, the first quarter-century: remarkable progress and outstanding questions
2012 Standout
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
2017
The biology and function of fibroblasts in cancer
2016 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Inhibition of α-helix-mediated protein–protein interactions using designed molecules
2013
Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors
2020
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
2020
Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets
2014
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
2020
Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets
2020
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities
2004
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Blinded by the Light: The Growing Complexity of p53
2009 Standout
A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells
2014 StandoutNobel
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
Dormancy of Solitary Metastatic Cells
2006
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Identification of Putative Target Genes of the Transcription Factor RUNX2
2013 StandoutNobel
Mitochondria are the primary target in the induction of apoptosis by chiral ruthenium(II) polypyridyl complexes in cancer cells
2013
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
2020
Targeting apoptosis in cancer therapy
2020 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
The essence of senescence: Figure 1.
2010 Standout
Intrinsically disordered proteins in cellular signalling and regulation
2014 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Targeted protein degradation: expanding the toolbox
2019
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
2017
The use of spirocyclic scaffolds in drug discovery
2014 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
2004 Standout
Melanoma × macrophage hybrids with enhanced metastatic potential
1998
Ubiquitination and phosphorylation in the regulation of NOD2 signaling and NOD2-mediated disease
2012
Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras
2021
Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism☆
2009
Does tumour dormancy offer a therapeutic target?
2010
Recruitment of the Linear Ubiquitin Chain Assembly Complex Stabilizes the TNF-R1 Signaling Complex and Is Required for TNF-Mediated Gene Induction
2009
In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)
2021
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
2020
An Organocatalytic [3+2] Cyclisation Strategy for the Highly Enantioselective Synthesis of Spirooxindoles
2010
Cancer as an evolutionary and ecological process
2006 Standout
Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth
1994
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
2019
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants
2009
Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication.
2000
Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways
2016
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.
1992
Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.
1991
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
2008
Clues from cell metabolism
2010 StandoutNatureNobel
Crystal Structures of Protein-Bound Cyclic Peptides
2019
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
2018
Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer
2000
Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma
2009
The Hitchhiker’s Guide to Flow Chemistry
2017 Standout
Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
2019
Multicellular resistance: a paradigm for clinical resistance?
2000
Rational Design of Topographical Helix Mimics as Potent Inhibitors of Protein–Protein Interactions
2014
Macrocyclic Modalities Combining Peptide Epitopes and Natural Product Fragments
2020
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Nonviral Vectors for Gene Delivery
2008 Standout
Phosphine Organocatalysis
2018 Standout
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis
2000 Standout
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development
2013
BET Proteins as Targets for Anticancer Treatment
2017
Fast Rescoring Protocols to Improve the Performance of Structure-Based Virtual Screening Performed on Protein–Protein Interfaces
2020
Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer
2005 StandoutNobel
PROTAC-DB: an online database of PROTACs
2020
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
New dimension in therapeutic targeting of BCL-2 family proteins
2015
Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
2021
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
PubChem 2023 update
2022 Standout
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
2013
Endogenous interleukin 6 can function as an in vivo growth- stimulatory factor for advanced-stage human melanoma cells.
1996
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Phosphine-Catalyzed Synthesis of 3,3-Spirocyclopenteneoxindoles from γ-Substituted Allenoates: Systematic Studies and Targeted Applications
2013
Synthetic Methods for Compounds Having CF3–S Units on Carbon by Trifluoromethylation, Trifluoromethylthiolation, Triflylation, and Related Reactions
2014
Identification of simple arylfluorosulfates as potent agents against resistant bacteria
2021 StandoutNobel
Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy
2019
Synthesis, in Vitro, and in Cell Studies of a New Series of [Indoline-3,2′-thiazolidine]-Based p53 Modulators
2013
A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
2019
Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality
2019
Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.
1990
PubChem in 2021: new data content and improved web interfaces
2020 Standout
Current strategies for the design of PROTAC linkers: a critical review
2020
Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
2014
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
2018
Stapled β-Hairpins Featuring 4-Mercaptoproline
2021 StandoutNobel
Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs
2020
Targeting IRAK4 for Degradation with PROTACs
2019
Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study
2004 Standout
Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis
2018 StandoutNobel
Unveiling the Mechanisms of Cell-Cell Fusion
2005 Science
The two faces of transforming growth factor β in carcinogenesis
2003 Standout
Works of Donna McEachern being referenced
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
2008
Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
2011
Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases
2011
Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
2015
SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP
2008
Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity
2021
Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment
2015
BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo
2014
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
2019
Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors
2013
Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia
1992
Inhibition of lung colonization at two different steps in the metastatic sequence
1991
Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development
2017
Design of the First‐in‐Class, Highly Potent Irreversible Inhibitor Targeting the Menin‐MLL Protein–Protein Interaction
2017
Sensitivity of human cells to mild hyperthermia.
1993
Potent and Orally Active Small-Molecule Inhibitors of the MDM2−p53 Interaction
2009
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
2017
A Potent Bivalent Smac Mimetic (SM-1200) Achieving Rapid, Complete, and Durable Tumor Regression in Mice
2013
Abstract 4870: Targeted MDM2 degradation as a novel and efficacious cancer therapy
2018
A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice
2013
Efficiency of communication between tumour cells in collagen gel cultures
1990
Growth regulation of mouse mammary tumor cells in collagen gel cultures by diffusible factors produced by normal mammary gland epithelium and stromal fibroblasts.
1989
Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM‐406/AT‐406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer
2013
Potent Bivalent Smac Mimetics: Effect of the Linker on Binding to Inhibitor of Apoptosis Proteins (IAPs) and Anticancer Activity
2011
Structure-Based Discovery of BM-957 as a Potent Small-Molecule Inhibitor of Bcl-2 and Bcl-xL Capable of Achieving Complete Tumor Regression
2012
Production of a more aggressive tumor cell variant by spontaneous fusion of two mouse tumor subpopulations.
1989
Structure-Based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in Vivo Antitumor Activity
2012
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
2018
Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles
2014
Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
2021
338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity
2014
A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment
2011
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
2019